908 Devices (NASDAQ:MASS – Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $11.90 million for the quarter.
908 Devices Price Performance
MASS stock opened at $5.63 on Monday. 908 Devices has a 52-week low of $1.81 and a 52-week high of $7.48. The company has a 50-day moving average of $4.44 and a two-hundred day moving average of $3.22. The stock has a market capitalization of $201.22 million, a price-to-earnings ratio of -3.18 and a beta of 0.26.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on MASS shares. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a report on Saturday. Stephens restated an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.33.
About 908 Devices
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Recommended Stories
- Five stocks we like better than 908 Devices
- How to Buy Gold Stock and Invest in Gold
- Constellation Powers Up With Reinforced AI Data Center Strategy
- What is diluted earnings per share (Diluted EPS)?
- Top Analyst-Rated Healthcare Stocks to Watch Now
- How to Short a Stock in 5 Easy StepsĀ
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.